Special Issue "Targeting the Epigenetic Machinery to Enhance Cancer Immunotherapy"

A special issue of Epigenomes (ISSN 2075-4655).

Deadline for manuscript submissions: closed (25 December 2020).

Special Issue Editors

Prof. Dr. Michael Chan
E-Mail Website
Guest Editor
Department of Biomedical Sciences, National Chung Cheng University, Chia Yi, Taiwan
Interests: cancer; epigenetics; biomarkers; bioinformatics; signaling pathway
Special Issues and Collections in MDPI journals

Special Issue Information

Dear Colleagues,

Cancer immunotherapy, such as immune checkpoint blockade, is effective against human cancer. However, only a subset of patients benefit from this novel therapy. It is, therefore, important to explore the mechanism behind this phenomenon. Recent evidence suggest that cancer cells may alter the epigenetic machinery, that controls RNA expression, for instance by DNA methylation and histon modifications, to evade the immune attack. In this special issue, we invite researchers to submit original research articles or reviews to uncover how targeting the epigenetic machinery can enhance cancer immunotherapy in human cancer.

Dr. Peter Kuppen
Prof. Michael Chan
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Epigenomes is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Related Special Issue

Published Papers (3 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Editorial

Jump to: Review

Open AccessEditorial
Firing up Cold Tumors—Targeting the Epigenetic Machinery to Enhance Cancer Immunotherapy
Epigenomes 2021, 5(2), 11; https://0-doi-org.brum.beds.ac.uk/10.3390/epigenomes5020011 - 03 May 2021
Viewed by 213
Abstract
Cancer immunotherapy using monoclonal antibodies targeting immune checkpoint proteins, such as PD-L1 or PD-1 (i [...] Full article
(This article belongs to the Special Issue Targeting the Epigenetic Machinery to Enhance Cancer Immunotherapy)
Show Figures

Figure 1

Review

Jump to: Editorial

Open AccessReview
Combinatorial Epigenetic and Immunotherapy in Breast Cancer Management: A Literature Review
Epigenomes 2020, 4(4), 27; https://0-doi-org.brum.beds.ac.uk/10.3390/epigenomes4040027 - 04 Dec 2020
Cited by 2 | Viewed by 835
Abstract
Breast cancer is one of the leading causes of death among cancer patients worldwide. To date, there are several drugs that have been developed for breast cancer therapy. In the 21st century, immunotherapy is considered a pioneering method for improving the management of [...] Read more.
Breast cancer is one of the leading causes of death among cancer patients worldwide. To date, there are several drugs that have been developed for breast cancer therapy. In the 21st century, immunotherapy is considered a pioneering method for improving the management of malignancies; however, breast cancer is an exception. According to the immunoediting model, many immunosuppressive cells contribute to immunological quiescence. Therefore, there is an urgent need to enhance the therapeutic efficacy of breast cancer treatments. In the last few years, numerous combinatorial therapies involving immune checkpoint blockade have been demonstrated that effectively improve clinical outcomes in breast cancer and combining these with methods of targeting epigenetic regulators is also an innovative strategy. Nevertheless, few studies have discussed the benefits of epi-drugs in non-cancerous cells. In this review, we give a brief overview of ongoing clinical trials involving combinatorial immunotherapy with epi-drugs in breast cancer and discuss the role of epi-drugs in the tumor microenvironment, including the results of recent research. Full article
(This article belongs to the Special Issue Targeting the Epigenetic Machinery to Enhance Cancer Immunotherapy)
Show Figures

Figure 1

Open AccessReview
Epigenetic Regulation of the Non-Coding Genome: Opportunities for Immuno-Oncology
Epigenomes 2020, 4(3), 22; https://0-doi-org.brum.beds.ac.uk/10.3390/epigenomes4030022 - 10 Sep 2020
Viewed by 1040
Abstract
The contribution of the non-coding genome to disease and its therapeutic potential have been largely unexplored. Recently, several epigenetic drugs developed for cancer treatment have been described to mediate therapeutic effects through the reactivation of the expression of transposable elements in cancer cells. [...] Read more.
The contribution of the non-coding genome to disease and its therapeutic potential have been largely unexplored. Recently, several epigenetic drugs developed for cancer treatment have been described to mediate therapeutic effects through the reactivation of the expression of transposable elements in cancer cells. This event activates innate immunity-related pathways and promotes the generation of neoantigens in tumor cells, improving the efficacy of immunotherapeutic treatments. This review focuses on the regulation of transposable elements by epigenetic inhibitors and its implications for immuno-oncology. Full article
(This article belongs to the Special Issue Targeting the Epigenetic Machinery to Enhance Cancer Immunotherapy)
Show Figures

Graphical abstract

Back to TopTop